- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01471743
GI Surgery Pre-Operative Nutrition
The Effect of Pre-Operative Immunonutrition With "Impact Advanced Recovery (R)" on Patients Undergoing Major GI Cancer Surgery
Surgical patients are high risk for post operative infections. These post operative infections contribute to increased length of hospital stay, hospital costs and delay overall recovery time thus decreasing the quality of life. Studies have reported post operative complications ranging from 37% to 74%.1 The most costly complications include infectious complications after major Gastrointestinal (GI) surgery including wound infections, abdominal abscess, pneumonia, sepsis and anastomic leaks.2 Several studies have been conducted that show a significant reduction in infectious complications and average length of stay when treated with immunonutrition supplements.2-3 A review of similarly designed studies in a different patient population indicate that post-operative infections can be reduced by an average of 71% with immunonutrition.
This study seeks to investigate the effect of Impact Advanced Recovery ® in improving surgical outcomes in patients receiving major gastrointestinal surgeries compared to a standard supplement at James A. Haley Veterans' Hospital. Providing Impact Advanced Recovery ® may decrease post-operative infectious complications, length of stay, and recovery time.
Hypothesis
In patients receiving elective gastrointestinal surgery (esophageal, gastric, pancreatic or colon resections) there will be a significant decrease of at least 60% in post-operative infections as listed below for patients who consume 15 servings of Impact Advanced Recovery® pre-operatively compared to patients who consume 15 servings of a standard supplement.
Complications to be considered: anastomatic leak, post-op wound development, post-op abdominal abscess, sepsis, pneumonia, post-op ileus, intestinal fistula, obstruction, urinary tract infections, peritonitis or bowel necrosis.
- In patients receiving elective gastrointestinal surgery (esophageal, gastric, pancreatic or colon resections) there will be a significant decrease in hospital and NPO days for patients who consume 15 servings of Impact Advanced Recovery ® pre-operatively.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- James A. Haley VA Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically documented neoplasm of the gastrointestinal tract.
- Planned major elective surgery including esophageal, gastric, pancreatic or colon resections.
Exclusion Criteria:
- Critically ill patients defined as any patient admitted to the intensive care unit (ICU) prior to elective surgery.
- Current use of steroids or other immunosuppressive medications.
- History of hospitalization for pulmonary, cardiac or renal disease in the 6 months prior to elective surgery.
- Patients who exhibit signs and symptoms of infection or sepsis including: elevated WBC above 10,000 cells/ml; temperature > 37.7 C
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Impact Advance Recovery (R)
3 supplements per day for 5 days pre-operatively
|
|
Active Comparator: Standard Supplement
3 supplement per day for 5 days pre-operatively
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with post-op Infections
Time Frame: within 30 days post-operatively
|
Determine the effectiveness of pre-operative supplementation with Impact Advanced Recovery ® on reducing the risk of developing complications during the 30 day post-operative period with decreased length of hospital stay, and time to resume an oral diet.
|
within 30 days post-operatively
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immunonutrition
-
Hospital General Universitario ElcheFundación Mutua MadrileñaCompleted
-
China Medical University, ChinaRecruitingGastrointestinal Tumors | Immunonutrition | Postoperative Adjuvant ChemotherapyChina
-
West China HospitalCompletedGastric Cancer | Enteral Immunonutrition
-
National Taiwan University HospitalRecruitingGastric Cancer | Gastrostomy | ImmunonutritionTaiwan
-
Cairo UniversityCompletedPain | Oral Cavity | Immunonutrition | Surgical Outcome | Mandibular TumorEgypt
-
Complexo Hospitalario Universitario de A CoruñaUnknownGastric Cancer | Esophageal Cancer | Surgery--Complications | Pancreas Cancer | ImmunonutritionSpain
-
Anhui Provincial HospitalRecruitingEsophageal Squamous Cell Carcinoma | Chemoradiotherapy | Immunonutrition | InoperableChina
-
Cancer Institute and Hospital, Chinese Academy...Active, not recruitingRadiotherapy | Sintilimab | Concurrent Chemoradiotherapy | Immunonutrition | Locally Advanced Esophageal Squamous Cell CarcinomaChina
Clinical Trials on Impact Advance Recovery (R)
-
University of Alabama at BirminghamActive, not recruitingCancer of Head and Neck | Nutrition Aspect of CancerUnited States
-
University Hospital, Clermont-FerrandCentre Leon Berard; Novartis; Centre Hospitalier Universitaire de Saint Etienne; Institut de Cancérologie de la Loire and other collaboratorsCompletedHead and Neck Cancer | Malnutrition | Esophageal CancerFrance
-
Greg MonohanTerminatedMultiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's LymphomaUnited States
-
Duke UniversityCompleted
-
University of Wisconsin, MadisonCompletedPancreaticoduodenectomy | EsophagectomyUnited States
-
University Medical Center GroningenHanze University of Applied SciencesRecruitingDepressionNetherlands
-
Jill Hamilton-Reeves, PhD RD LDAmerican Cancer Society, Inc.; Société des Produits Nestlé (SPN)CompletedUrinary Bladder Neoplasms | Surgery | Bladder Cancer | Radical CystectomyUnited States
-
University of Vic - Central University of CataloniaCompleted
-
University of Alabama at BirminghamWithdrawnInflammatory Bowel Diseases
-
Life Recovery SystemsNot yet recruitingST-Elevation Myocardial InfarctionUnited States